Library Item - Page 11 of 792 Posts on Medivizor

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Posted by Medivizor on Mar 16, 2023 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor...

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Posted by Medivizor on Mar 15, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of fertility preservation with ovarian stimulation on breast cancer and pregnancy outcomes in young women with breast cancer (BC). The data showed that fertility preservation was safe and did impact BC outcomes. Some background Breast cancer (BC) is one of the most common cancers affecting women...

Is osteoporosis more likely to occur in patients with rheumatoid arthritis?

Posted by Medivizor on Mar 13, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the occurrence of osteoporosis (OP) in patients with rheumatoid arthritis (RA). The authors concluded that although significant advancements were made in OP prevention, treatment and diagnosis, a high occurrence was still observed in patients with RA. Some background OP commonly occurs in patients with RA. It...

Is real time glucose monitoring better than intermittent scanning for patients with type 1 diabetes?

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study compared intermittent scanning continuous glucose monitoring (isCGM) with real-time continuous glucose monitoring (rtCGM) for the treatment of type 1 diabetes (T1D). It found that compared to isCGM, rt CGM resulted in increased time spent in range and improved blood glucose control in these patients. Some background...

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by Medivizor on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by Medivizor on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated. Some background DPNP occurs in patients...

Reviewing the significance of very low carbohydrate diets in type 2 diabetes.

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effect of very low carbohydrate (VLC) or ketogenic diets (KDs) with higher carbohydrate diets in patients with pre-diabetes or type 2 diabetes (T2D). The data showed that reduced levels of glycated hemoglobin (HbA1c) and triglycerides may occur with VLC or KDs, but with limited advantages over other diets. Some...

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Posted by Medivizor on Mar 5, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study explored the effectiveness and safety of tripterygium glycosides (TG) as a disease-modifying anti-rheumatic drug (DMARD) when combined with conventional DMARDs for treating rheumatoid arthritis (RA). The authors concluded that good safety and better improvements in RA symptoms were observed when TG was combined with a...

Can once-weekly administered semaglutide reduce adipose tissue and fat in patients with type 2 diabetes?

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effect of subcutaneous semaglutide (Ozempic) on body composition in patients with type 2 diabetes (T2D). The data showed significant weight loss in these patients after 3 months of semaglutide treatment based on reduced visceral adipose tissue (VAT) thickness and fat mass (FM). Some background T2D is...

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by Medivizor on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Library Item Posts on Medivizor

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Is osteoporosis more likely to occur in patients with rheumatoid arthritis?

Is real time glucose monitoring better than intermittent scanning for patients with type 1 diabetes?

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Reviewing the significance of very low carbohydrate diets in type 2 diabetes.

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Can once-weekly administered semaglutide reduce adipose tissue and fat in patients with type 2 diabetes?

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Categories

Recent Posts

Archives

Library Item Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email